54 Matching Annotations
  1. Last 7 days
  2. Apr 2021
  3. Mar 2021
    1. Hilda Bastian, PhD. (2021, February 6). Unofficial unnamed AstraZeneca insider says they are doing the interim analysis for the US trial of the Oxford vaccine. AstraZeneca spokesperson says 4-6 weeks till data release. Https://t.co/VUHgbHN02d One is wrong? Or they’ll release only when have FDA minimum follow-up? Https://t.co/LgjfX8AIti [Tweet]. @hildabast. https://twitter.com/hildabast/status/1357862227106095105

    1. Voysey, M., Costa Clemens, S. A., Madhi, S. A., Weckx, L. Y., Folegatti, P. M., Aley, P. K., Angus, B. J., Baillie, V., Barnabas, S. L., Bhorat, Q. E., Bibi, S., Briner, C., Cicconi, P., Clutterbuck, E., Collins, A. M., Cutland, C., Darton, T., Dheda, K., Douglas, A. D., … Group, O. C. V. T. (2021). Single Dose Administration, And The Influence Of The Timing Of The Booster Dose On Immunogenicity and Efficacy Of ChAdOx1 nCoV-19 (AZD1222) Vaccine (SSRN Scholarly Paper ID 3777268). Social Science Research Network. https://papers.ssrn.com/abstract=3777268

    1. Emary, K. R. W., Golubchik, T., Aley, P. K., Ariani, C. V., Angus, B. J., Bibi, S., Blane, B., Bonsall, D., Cicconi, P., Charlton, S., Clutterbuck, E., Collins, A. M., Cox, T., Darton, T., Dold, C., Douglas, A. D., Duncan, C. J. A., Ewer, K., Flaxman, A., … Group, O. C. V. T. (2021). Efficacy of ChAdOx1 nCoV-19 (AZD1222) Vaccine Against SARS-CoV-2 VOC 202012/01 (B.1.1.7) (SSRN Scholarly Paper ID 3779160). Social Science Research Network. https://doi.org/10.2139/ssrn.3779160

    1. Yufika, A., Wagner, A. L., Nawawi, Y., Wahyuniati, N., Anwar, S., Yusri, F., Haryanti, N., Wijayanti, N. P., Rizal, R., Fitriani, D., Maulida, N. F., Syahriza, M., Ikram, I., Fandoko, T. P., Syahadah, M., Asrizal, F. W., Aletta, A., Haryanto, S., Jamil, K. F., … Harapan, H. (2020). Parents’ hesitancy towards vaccination in Indonesia: A cross-sectional study in Indonesia. Vaccine, 38(11), 2592–2599. https://doi.org/10.1016/j.vaccine.2020.01.072

    1. David Benkeser. (2020, November 9). Another view on uncertainty associated based on Pfizer’s results. Even if you were highly skeptical about MRNA vaccines (many are [were?]) with 50% prior belief that VE ~ 0, based on an 8:86 vax:placebo case split, the posterior probability that VE > 75% is ~ 1. Https://t.co/xtBONtGHmT [Tweet]. @biosbenk. https://twitter.com/biosbenk/status/1325856366225993729

  4. Feb 2021
    1. Carl T. Bergstrom. (2021, January 31). A somewhat technical thread about measuring vaccine efficacy. We’re used to the notion that certain properties of tests for disease depend on prevalence: Positive and negative predictive value do, for example, whereas sensitivity and specificity do not. [Tweet]. @CT_Bergstrom. https://twitter.com/CT_Bergstrom/status/1355762090078703621

    1. Wibmer, C. K., Ayres, F., Hermanus, T., Madzivhandila, M., Kgagudi, P., Lambson, B. E., Vermeulen, M., Berg, K. van den, Rossouw, T., Boswell, M., Ueckermann, V., Meiring, S., Gottberg, A. von, Cohen, C., Morris, L., Bhiman, J. N., & Moore, P. L. (2021). SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma. BioRxiv, 2021.01.18.427166. https://doi.org/10.1101/2021.01.18.427166

  5. Jan 2021
    1. ReconfigBehSci. (2020, November 9). RT @peterbachmd: Relevant today: Ever sharp @nataliexdean on Vaccine Effectiveness vs Efficacy from many moons ago (i.e. About a month). Sh… [Tweet]. @SciBeh. https://twitter.com/SciBeh/status/1325889181097267200

  6. Dec 2020
    1. Voysey, M., Clemens, S. A. C., Madhi, S. A., Weckx, L. Y., Folegatti, P. M., Aley, P. K., Angus, B., Baillie, V. L., Barnabas, S. L., Bhorat, Q. E., Bibi, S., Briner, C., Cicconi, P., Collins, A. M., Colin-Jones, R., Cutland, C. L., Darton, T. C., Dheda, K., Duncan, C. J. A., … Zuidewind, P. (2020). Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. The Lancet, 0(0). https://doi.org/10.1016/S0140-6736(20)32661-1

  7. Nov 2020
  8. Sep 2020
    1. Natalie E. Dean en Twitter: “VACCINE EFFICACY 101: A biostatistician's primer. Ten tweets to cover:- How is vaccine efficacy calculated?- Distinguishing between infection, disease, & severe disease.- Measuring reduced infectiousness.- Vaccine efficacy vs. effectiveness!n” / Twitter. (n.d.). Twitter. Retrieved September 30, 2020, from https://twitter.com/nataliexdean/status/1310613702476017666

  9. Aug 2020
    1. Zhu, F.-C., Guan, X.-H., Li, Y.-H., Huang, J.-Y., Jiang, T., Hou, L.-H., Li, J.-X., Yang, B.-F., Wang, L., Wang, W.-J., Wu, S.-P., Wang, Z., Wu, X.-H., Xu, J.-J., Zhang, Z., Jia, S.-Y., Wang, B.-S., Hu, Y., Liu, J.-J., … Chen, W. (2020). Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: A randomised, double-blind, placebo-controlled, phase 2 trial. The Lancet, 0(0). https://doi.org/10.1016/S0140-6736(20)31605-6